Fringe Tech Moves: Nutanix Leads as Leveraged ETFs Face Brutal Shakeout

Unorthodox sectors and miscellaneous tickers are seeing a significant reshuffle this week. I'm told that as capital rotates quickly, select hybrid cloud and semiconductor infrastructure plays are showing surprising resilience, while several high-risk leveraged products face a brutal shakeout.

Nutanix (NTNX.US)

Nutanix’s momentum in hybrid multi-cloud and AI application support has caught Wall Street's attention. According to people familiar with the matter, the company blew past the high end of its guidance in fiscal Q3 2026, with quarterly revenue climbing 10% to USD 703M and annual revenue topping USD 2.5B. Sources say that with over 50% of the Global 2000 now trusting their platform, their latest innovations in AI and external storage are monetizing faster than expected. This marks what could be a major overhaul in the sector's growth trajectory this year.

Semtech (SMTC.US)

As a key player in analog and mixed-signal semiconductors, Semtech has also been outpacing market expectations. Revenue for fiscal Q1 2027 reached USD 291M, up nearly 15.9% year-over-year, alongside a solid 37% jump in net income. However, I'm told recent insider selling is worth noting; a director recently offloaded shares, and insiders have collectively dumped over USD 3.2M in stock over the past quarter. This might signal short-term valuation pressures following their recent rally.

Yimutian (YMT.US)

The Chinese agricultural B2B platform Yimutian is navigating a critical juncture in the capital markets. I've learned the company recently executed a ratio change equivalent to a 1-for-15 reverse split and was just approved to transfer to the Nasdaq Capital Market. They have until September 2026 to prove compliance with the USD 1.00 minimum bid requirement, meaning the clock is ticking for management.

Hang Feng Technology Innovation (FOFO.US)

This Hong Kong-based management consultancy is making bold moves. I'm told its wholly-owned subsidiary recently secured a Type 1 dealing in securities license from the Hong Kong SFC in July 2026. Despite total revenue growing in fiscal 2025, massive non-cash R&D expenses resulted in notable net losses, so they will need to monetize this new license quickly.

Also

• ProShares Ultra SK Hynix ETF (SKHU.US): I'm told the compounding effect of daily resets has been catastrophic here, with SK Hynix ADR's recent decline triggering a plunge of over 50% for this leveraged vehicle.
• NEOS Bitcoin High Income ETF (BTCI.US): Despite a significant pullback since peaking last year, the fund's double-digit distribution rate and options overlay strategy are helping to offset some downward pressure.
• Aeluma (ALMU.US): The non-InP photonic semiconductor developer recently signed a non-binding letter of intent with the CHIPS R&D Office, setting the stage for up to USD 30M in proposed funding.
• Meridian Bioscience (VIVO.US): Following its acquisition, the company's diagnostics division remains a bright spot, though the broader life sciences segment has faced post-merger integration headwinds.
• MKS Instruments (MKSI.US): The critical subsystem supplier for semiconductor manufacturing continues to navigate the cyclical demand shifts of the broader equipment industry later this year.
• Tradr 2X Long AXTI Daily ETF (AXTC.US): Volatility in this leveraged ETF has spiked, fueled by underlying asset AXT Inc.'s blowout Q2 2026 results, which saw revenue jump 165% to USD 47.6M.

This article does not constitute investment advice.